Option chain shows key data for Matinas BioPharma Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Matinas BioPharma Hldgs.

Matinas BioPharma Hldgs (AMEX:MTNB) Stock, Option Chain

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

xr:d:DAFfORZ4lNo:2,j:2185570849,t:23040509

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

BAER

BNOX

BTCT

CERO

DXYZ

GRAB

LAZR

LGMK

LIFW

Eaton Vance Massachusetts Municipal Income Trust

NGNE

OGEN

TAOP

Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Uber stock

Earnings

Equities

Eurozone

Commodities

Intraday Update

ATEC

CMPS

LMND

ROOT

UBER

Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

Although Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is up over 190% year-to-date, &#8220;over the last five months the stock has been relatively flat, leaving bulls and bears at an inflection point,&#8221; <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40652895/exclusive-beyond-the-magnificent-seven-direxions-egilinsky-reveals-top-sector-picks">Direxion&#8216;s Ed Egilinsky says</a>.
This pause in growth signals the stock might be priced to perfection. Some active traders are watching for the next move. 
For those who consider the stock&#8217;s price is perfection and forward expectations are not lofty enough to propel it higher, the Direxion Daily NVDA Bear 1X Shares ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>) offers a way to get profit from any expected correction in the stock. 
However, traders who believe the stock will trend higher in the short term, can look to trade the Direxion Daily NVDA Bull 2X Shares ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>).
Read Also: <a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips">Jim Cramer Doubles Down On Nvidia: &#8216;Demand Is Accelerating&#8217; As AI Customers &#8216;Have No Choice&#8217; But To Buy Its Chips</a>
<h2 class="wp-block-heading">Potential R&amp;D Spending Not Baked In</h2>
While Nvidia remains the barometer for the AI space, Egilinsky stresses the importance of continued innovation to retain its competitive edge in AI chips. 
&#8220;This could result in a more sizable commitment to their R&amp;D spending that might not be totally baked into current projections,&#8221; he said.
<h2 class="wp-block-heading">Geopolitical Tensions, Tariffs Could Impact Future Growth</h2>
Beyond its product and performance, Nvidia's future is increasingly shaped by geopolitical risks, particularly the U.S. tariff stance. 
&#8220;Traders will be waiting for a sign to trade the next move in Semis and for short-term traders that can be either a bullish view or bearish sentiment,&#8221; Egilinsky said.
The Donald Trump administration's policies on global trade, especially tariffs, could affect Nvidia's revenue from China and its reliance on Taiwan for chip production.
<h2 class="wp-block-heading">AI Growth Still Promising, But Tariffs Add Uncertainty</h2>
Despite these risks, Nvidia's future looks promising, especially with Blackwell shipments ramping up next quarter. 
One way to gauge Nvidia's AI growth prospects is by looking at its key customers like Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). 
These tech giants rely heavily on Nvidia's chips to power their cloud platforms, machine learning, and data centers. As these companies expand their AI operations, Nvidia's role in driving this growth could bolster its position in the market, fueling continued demand for its products.
Egilinsky said the excessive demand for Nvidia&#8217;s products might &#8220;send the stock to new all-time highs.&#8221; Still, the company's ability to navigate geopolitical hurdles will be crucial to sustaining this growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a></li>
</ul>

Analyst Color

Long Ideas

Analyst Ratings

AMZN

MSFT

NVDA

NVDD

NVDU

Nvidia 'Bulls And Bears At An Inflection Point,' Expert Says: Will AI Growth Overcome Global Tariff Risks?

<a href="https://www.ft.com/content/739bed04-fce1-4429-bbfd-64979e6bf395">https://www.ft.com/content/739bed04-fce1-4429-bbfd-64979e6bf395</a>

'Unilever To Slim Down But Not Spin Off Food Business, Says Chief' - Financial Times

RBC Capital analyst Rishi Jaluria maintains Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) with a Outperform and raises the price target from $32 to $36.

Price Target

CWAN

RBC Capital Maintains Outperform on Clearwater Analytics Hldg, Raises Price Target to $36

WIIM

Nano Labs shares are trading higher after the company announced it unveiled a second-generation of v series crypto mining products with 5x the power efficiency.

QMCO

Quantum Shares Halted On Circuit Breaker To The Downside, Stock Now Up 52.2%

Nutanix's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NYSE">NTNX</a>) short percent of float has fallen 11.79% since its last report. The company recently reported that it has 4.65 million shares sold short, which is 2.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nutanix Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732290320_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nutanix has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Nutanix's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nutanix's peer group average for short interest as a percentage of float is 3.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

NTNX

(NTNX) - Analyzing Nutanix's Short Interest

MSP Recovery shares are trading higher after the company announced it secured a $2 million pharmaceutical settlement.

CSW Industrials's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSWI#NYSE">CSWI</a>) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 397 thousand shares sold short, which is 2.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CSW Industrials Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732290315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CSW Industrials has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CSW Industrials's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CSW Industrials's peer group average for short interest as a percentage of float is 3.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CSWI

(CSWI) - Analyzing CSW Industrials's Short Interest

New York&#8217;s storied real estate dynasties are breaking a rule passed down through generations – never sell your buildings. As the <a href="https://www.benzinga.com/real-estate/24/10/41357339/experts-warn-that-distress-in-u-s-offices-may-lead-to-a-surging-supply-of-one-billion-square-feet-of">office market crumbles under the weight of remote work</a>, New York families are forced to part with properties they&#8217;ve held for decades.
William Rudin, whose family helped shape Manhattan&#8217;s skyline, recently sold control of two financial district towers his family developed in the 1960s. "The world has changed," Rudin, the co-executive chairman of his family's firm, told the Wall Street Journal. "We have to take a cold hard look at our business to make sure there's a foundation for the next generation."
Don't Miss:
<ul>
<li>Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
The sales mark a shift for families that have weathered world wars, financial crashes and even a pandemic without letting go of their core assets. According to real estate investment firm Eastdil Secured, New York&#8217;s real estate families have sold about 10 office buildings in the past two years – double the number sold in the previous decade.
"Instead of 50 different aunts and uncles getting distributions, they're getting capital calls," Gary Phillips, an Eastdil managing director, told the WSJ, highlighting the financial strain on extended family businesses.
With a 100-year legacy in Manhattan real estate, the Kaufman family is also reluctantly selling. "We and the other families did not sell," Jonathan Iger, CEO of Sage Realty, the Kaufman family's management firm, said to the WSJ. "You see yourself through the dips and you come out – not just fine, but more than fine."
Trending: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
Some families are fighting to hold on. The Gurals recently invested fresh capital into their 60-year-old DuMont Building on Madison Avenue. "It's called a capital call, which is the most dreaded term in our industry," said Jeffrey Gural, chairman of GFP Real Estate. Despite the pain, Gural remains convinced holding is the right choice. "I have yet to sell a building where I didn't regret selling," he said.
For the Rudins, even a $100 million renovation at 80 Pine Street couldn't save it from the chopping block. "Even if we spent money to fix up the building, the ceilings are too low, there are a lot of columns, the floors are too big," Rudin explained. "It became clear to us we needed to stop putting capital back into the building."
The sales represent more than just business decisions – they're the end of an era for families who built New York's commercial landscape. "When I go by 80 Pine Street, I remember the good times and bad times," Rudin reflected. "But you've got to move on."
The shift might signal a broader transformation in urban real estate, as aging office towers face obsolescence in a <a href="https://www.benzinga.com/markets/24/08/40436855/hopes-for-nyc-office-market-rebound-dented-by-sale-of-midtown-skyscraper-at-97-discount-but-theres-a">post-pandemic world demanding modern amenities and flexible workspaces</a>.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

'I Have Yet to Sell A Building Where I Didn't Regret Selling ': Families Forced To Sell NYC Icons

Comfort Systems USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) short percent of float has risen 40.65% since its last report. The company recently reported that it has 536 thousand shares sold short, which is 2.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Comfort Systems USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732290310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Comfort Systems USA has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Comfort Systems USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Comfort Systems USA's peer group average for short interest as a percentage of float is 4.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(FIX) - Analyzing Comfort Systems USA's Short Interest

RBC Capital analyst Arun Viswanathan reiterates Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Sector Perform and maintains $105 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Eastman Chemical, Maintains $105 Price Target

- Court Document
<figure class="image"><img src="https://pbs.twimg.com/media/Gc_-b5VWAAAMhj1?format=jpg&amp;name=large" alt="Image" /></figure>

Macro Economic Events

Politics

Legal

Economics

General

New York Judge Grants Trump Permission To File Motion To Dismiss Hush Money Case, Delays Sentencing

CTXR

Citius Pharmaceuticals shares are trading lower after the company announced a 1-for-25 reverse stock split.

The S&amp;P 500 index is wrapping up a historic two-year run of consecutive over 20% gains, a feat achieved only four times in the past 150 years. Yet, Michael Hartnett, chief investment strategist at Bank of America, says the party <a href="https://www.benzinga.com/markets">may not last forever. </a>
According to Hartnett&#8217;s latest Flow Show report, published Friday, the U.S. equity market is poised for another &#8220;double-digit move&#8221; in 2025 — though investors shouldn't rule out the possibility of a second wave of inflation that could derail the bull market.
The Bank of America&#8217;s Investment Clock — a key barometer that shows the prevailing economic scenario in a given year — is transitioning from a &#8220;recovery&#8221; in 2024 to an &#8220;inflation boom&#8221; in 2025.
<h1 class="wp-block-heading">History Rhymes: Rare Consecutive Gains</h1>
The S&amp;P 500 — as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — surged 24% in 2024, mirroring its 24% rally in 2023.
This back-to-back streak of 20%-plus returns happened just four times in the past century and a half: during 1927-&#8217;28, 1935-&#8217;36, 1954-&#8217;55, and 1995-&#8217;96.
However, history shows that the years following such rallies often see wild market swings, for better or worse.
<ul>
<li>1927-28: Followed by a -12% loss in 1929 and a catastrophic -28% drop in 1930.</li>
<li>1935-36: After two years of outsized returns, 1937 saw a brutal -39% decline.</li>
<li>1954-55: Markets cooled, with modest gains of +3% in 1956 and a -14% slide in 1957.</li>
<li>1995-96: Continued strength with a +31% gain in 1997 but slowed to +12% in 1998.</li>
</ul>
Will 2025 follow a similar script? Hartnett says a major move — up or down — should be expected.
<h1 class="wp-block-heading">3 Reasons Why The S&amp;P 500 Could Rise In 2025</h1>
Hartnett highlights three key drivers that can pave the way for the bull market to continue in 2025.
<ol>
<li>A "boomy" economic backdrop: Companies are front-loading operations ahead of potential tariffs, labor hoarding remains rampant amid tighter immigration controls and unemployment claims have tumbled. </li>
<li>Goldilocks bond yields: Despite $36 trillion in U.S. debt and a 7% GDP deficit, central banks are expected to cut rates in 2025 — Bank of America is forecasting 124 global rate cuts. </li>
<li>Political incentives: The Trump administration is heavily invested in propping up risk assets like equities and cryptocurrencies to stimulate &#8220;animal spirits,&#8221; making a bear market unlikely heading into an election year.</li>
</ol>
<h1 class="wp-block-heading">&#8230; Yet Valuations Are Stretched To Extremes</h1>
With the S&amp;P 500&#8217;s trailing price-to-earnings ratio now at 26.5x, it ranks as the fourth-highest valuation in 125 years, behind only December 1921, June 1999 and June 2021.
The U.S. stock market is sitting at 75-year highs relative to international equities, with just 10 companies accounting for a staggering 37% of market cap.
This concentration has been driven by the so-called &#8220;Magnificent Seven&#8221; tech giants — stocks whose collective market capitalization surged by $4 trillion in 2024.
But Hartnett indicates the narrative of U.S. exceptionalism, particularly in artificial intelligence, may be peaking cyclically.
Crunching the numbers, he highlighted that the S&amp;P 500&#8217;s secular bull market, which began at 666 points in March 2009, could potentially climax at 6,666 in 2025.
<h1 class="wp-block-heading">&#8230; And Inflation May Return</h1>
Bank of America's Investment Clock model indicates 2024 marked an equity-bullish "recovery" phase, driven by lower rates and higher corporate earnings.
But 2025 could transition into an "inflation boom" phase, where rising rates and price pressures become the dominant themes.
While Hartnett is bullish on commodities as a hedge against this scenario, he warns credit and equities may peak in early 2025.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios">2025 US Economy Outlook &#8216;Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>
Photo: Shutterstock

S&P 500 Faces Volatile 2025 As 'Inflation Boom' Could Return: Bank Of America Strategist

ANIX

Anixa Biosciences shares are trading higher after the company announced it approved Bitcoin purchases and is continuing its stock buyback program.

GEOS

Geospace Technologies shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

RBC Capital analyst Matthew Hedberg maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Outperform and raises the price target from $110 to $130.

ESTC

RBC Capital Maintains Outperform on Elastic, Raises Price Target to $130

<ul>
<li>MSTR</li>
<li>ACHR</li>
<li>NVDA</li>
<li>$BTC</li>
<li>SMCI</li>
<li>TSLA</li>
<li>RKLB</li>
<li>CORN</li>
<li>LUNR</li>
<li>RDDT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

ACHR

CORN

LUNR

MSTR

RDDT

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 22, 2024 (Via Swaggy Stocks)

RBC Capital analyst Chris Dendrinos maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Sector Perform and lowers the price target from $85 to $71.

ENPH

RBC Capital Maintains Sector Perform on Enphase Energy, Lowers Price Target to $71

Quantum Shares Halted On Circuit Breaker To The Upside, Stock Now Up 60.5%

Matinas BioPharma Holdings, Inc. 2024 Q2 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Matinas BioPharma Hldgs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/">MTNB</a>) just reported results for the second quarter of 2024.<ul><li>Matinas BioPharma Hldgs reported earnings per share of -2 cents. This met the analyst estimate for EPS of -2 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mtnb-stock-earnings-matinas-biopharma-hldgs-for-q2-of-2024/">MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024

Matinas BioPharma (MTNB) has provided an update. The Company has updated its corporate presentation for use at upcoming conferences and investor me...

Matinas BioPharma Releases Updated Corporate Presentation

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price...

Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development

These are the upcoming stock splits for the week of September 2 to September 6, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a c...

Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested

Maxim downgraded Matinas BioPharma (MTNB) to Hold from Buy. The company announced that partnering negotiations for its lead asset MAT2203 – oral am...

Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks

Matinas BioPharma plunges as deal for lead asset falls apart

Alliance Global Partners downgraded Matinas BioPharma (MTNB) to Neutral from Buy without a price target after the company announced that negotiatio...

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

Matinas BioPharma Holdings (MTNB) has disclosed a new risk, in the Innovation / R&D category. Matinas BioPharma Holdings faces significant business...

Matinas BioPharma Faces Uncertain Future After Halting MAT2203 Development

DPRO

WRIV

Press Releases

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Health Care

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Comments

Matinas BioPharma Hldgs

Matinas BioPharma Hldgs (MTNB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga